Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01703481 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 188
- Enrollment target
NCT01703481 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 188 participants.
The verdict
NCT01703481, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 188 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, pharmacokinetics (study of what the body does to a drug), and pharmacodynamics (study of what a drug does to the body) of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in adult participants with advanced or refractory solid tumors or lymphoma.
Interventions
- DRUG JNJ-42756493: Part 1
- DRUG JNJ-42756493: Part 2
- DRUG JNJ-42756493: Part 3
- DRUG JNJ-42756493: Part 4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2012-06-15 |
| Est. Completion | 2017-07-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01703481
The ClinicalTrials.gov registry entry for NCT01703481 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which JNJ-42756493: Part 1 is the first listed.
NCT01703481 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01703481 about?
NCT01703481 is a clinical study titled "A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma". The purpose of this study is to evaluate the safety, pharmacokinetics (study of what the body does to a drug), and pharmacodynamics (study of what a drug does to the body) of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in adult participants with advanced o...
What is the current status of trial NCT01703481?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 188 participants. The study started on 2012-06-15. Estimated completion is 2017-07-05.
What interventions are being tested in trial NCT01703481?
The interventions under investigation include: JNJ-42756493: Part 1 (DRUG), JNJ-42756493: Part 2 (DRUG), JNJ-42756493: Part 3 (DRUG), JNJ-42756493: Part 4 (DRUG).
Who is sponsoring clinical trial NCT01703481?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.